米托蒽醌
米托蒽醌(Mitoxantrone)
CAS: 65271-80-9
化学式: C22H28N4O6
| 中文名 | 米托蒽醌 |
| 英文名 | Mitoxantrone |
| 别名 | 米拖蒽醌 米托蒽醌 米托恩醌 盐酸米托蒽醌 (HPLC) 拓扑异构酶II(TOPOISOMERASE II)抑制剂(MITOXANTRONE) 1,4-二羟基-5,8-双[[2-[(2-羟乙基)氨基]乙基]氨基]-9,10-蒽醌 1,4-二羟基-5,8-二[[2-[(2-羟基乙基)氨基]乙基]氨基]蒽-9,10-二酮 |
| 英文别名 | DHAQ MITOXANTRONE Mitoxantrone MITOXANTRONUM mitoxanthrone MitoxantroneBase 1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedi 1,4-Dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethylamino]-9,10-anthraquinone 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-anthracene-9,10-dione 1,4-Dihydroxy-5,8-Bis((2-((2-Hydroxyethyl)Amino)Ethyl)Amino)Anthracene-9,10-Dione 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione |
| CAS | 65271-80-9 |
| EINECS | 1533716-785-6 |
| 化学式 | C22H28N4O6 |
| 分子量 | 444.48 |
| InChI | InChI=1/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2 |
| 密度 | 1.3049 (rough estimate) |
| 熔点 | 170-1740C |
| 沸点 | 554.47°C (rough estimate) |
| 闪点 | 441.1°C |
| 蒸汽压 | 2.05E-27mmHg at 25°C |
| 溶解度 | DMSO (微溶) 、甲醇 (微溶) 、水 (微溶) |
| 折射率 | 1.6500 (estimate) |
| 酸度系数 | pKa 5.99 (Uncertain);8.13 (Uncertain) |
| 存储条件 | Keep in dark place,Sealed in dry,2-8°C |
| 敏感性 | Easily absorbing moisture |
| 外观 | 固体 |
| 颜色 | Dark Blue to Black |
| 物化性质 | 蓝黑色结晶。熔点203-205℃。略溶于水，微溶于乙醇，不溶于氯仿和丙酮。无臭，易吸潮 |
| MDL号 | MFCD00242942 |
| 体外研究 | Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its K i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP. Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 μg/mL) induces a decrease in cell viability. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of mitoxantrone is due to induction of apoptosis. Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC 50 values of 18 and 196 nM, respectively. |
| 体内研究 | Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produces a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also shows effective antitumor activities and produces a 60% and a 45% ILS, respectively.. |
| 危险品标志 | T - 有毒物品 T+ - 极高毒性物品  |
| 风险术语 | R46 - 可能引起遗传性基因损害。 R61 - 可能对胎儿造成伤害。 R26/27/28 - 吸入、皮肤接触及吞食有极高毒性。 |
| 安全术语 | S53 - 避免接触，使用前须获得特别指示说明。 S36/37/39 - 穿戴适当的防护服、手套和护目镜或面具。 S45 - 若发生事故或感不适，立即就医(可能的话，出示其标签)。 S22 - 切勿吸入粉尘。 |
| WGK Germany | 3 |
| RTECS | CB5748500 |
| 上游原料 | 四氯苯醌 |
| 参考资料 展开查看 | 1. [IF=3.119] Jinrui Zhang et al."In silico study on identification of novel MALT1 allosteric inhibitors."Rsc Adv. 2019 Nov;9(67):39338-39347 2. [IF=3.765] Yu Xuan et al.An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation.J Pharm Pharmacol. 2021 Nov;: |
供应商列表
米托蒽醌的上游原料
您刚刚浏览过
你知道吗？
微信搜索化工百科或扫描下方二维码，添加化工百科小程序，随时随地查信息！